The reiteration of a Buy rating and the maintenance of a $21 price target by a reputable analyst like Mike Matson from Needham could lead to increased investor confidence in NeoGenomics. This positive endorsement is likely to have a favorable impact on the stock price in the short term as it suggests that the analyst sees potential for the stock to grow and reach the set target.